Immunohistochemical study of arginase 1 and 2 in various tissues of rats

Choi, Sungyoung; Park, Changnam; Ahn, Meejung; Lee, Jun Hwa; Shin, Taekyun

doi:10.1016/j.acthis.2011.09.002

Cited by 64 publications

(56 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…25 Arginase staining may rarely be seen in other tumors but has not been described in cholangiocarcinoma. 25,43 Positive arginase staining was observed in 85% of scirrhous hepatocellular carcinomas and none of the cholangiocarcinomas in our study. Notably, the combined use of GPC3 and arginase identified all cases of scirrhous hepatocellular carcinoma.…”

Section: Discussionmentioning

confidence: 66%

Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma

et al. 2013

View full text Add to dashboard Cite

Scirrhous hepatocellular carcinoma is a rare ill-defined morphological subtype of hepatocellular carcinoma characterized by marked stromal fibrosis. This variant can be difficult to distinguish from intrahepatic cholangiocarcinoma and metastatic adenocarcinoma, especially on needle biopsies. We performed immunohistochemistry for hepatocellular and adenocarcinoma-associated markers on 20 scirrhous hepatocellular carcinoma cases and compared the results with classical hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Scirrhous hepatocellular carcinomas were significantly less likely to be HepPar-1 positive than classical hepatocellular carcinomas (26% and 74%, respectively; Po0.001) and were significantly more likely to express adenocarcinoma-associated markers such as epithelial cell adhesion molecule (63 vs 11%; Po0.001), cytokeratin 19 (26 vs 2%; Po0.001), and cytokeratin 7 (53 vs 2%; Po0.001). At least one of these adenocarcinoma-related markers was positive in 80% of scirrhous hepatocellular carcinoma cases. Glypican 3 and arginase were positive in 79% and 85% of cases of scirrhous hepatocellular carcinoma, respectively; the combined use of these two markers yielded 100% sensitivity for scirrhous hepatocellular carcinoma. In conclusion, the scirrhous morphology, absence of HepPar-1 staining, and frequent positivity with adenocarcinoma-related markers in scirrhous hepatocellular carcinoma can lead to an erroneous diagnosis of adenocarcinoma. Glypican 3 and arginase are the most reliable markers for identifying hepatocellular differentiation in this setting.

show abstract

Section: Discussionmentioning

confidence: 66%

Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma

et al. 2013

View full text Add to dashboard Cite

show abstract

“…A, Cellular arginine metabolism and putative role of arginase in the development of renal fibrosis. ARG1 is a cytosolic enzyme known to be expressed in the kidney (68,69). It was originally identified in liver hepatocytes, where it catalyzes the hydrolysis of L-arginine to L-ornithine and urea in the final step of the urea cycle that allows ammonia detoxification (70).…”

Section: Discussionmentioning

confidence: 99%

Label-free Quantitative Urinary Proteomics Identifies the Arginase Pathway as a New Player in Congenital Obstructive Nephropathy

Lacroix

Caubet

Peredo

et al. 2014

Molecular & Cellular Proteomics

View full text Add to dashboard Cite

Obstructive nephropathy is a frequently encountered situation in newborns. In previous studies, the urinary peptidome has been analyzed for the identification of clinically useful biomarkers of obstructive nephropathy. However, the urinary proteome has not been explored yet and should allow additional insight into the pathophysiology of the disease. We have analyzed the urinary proteome of newborns (n ‫؍‬ 5/group) with obstructive nephropathy using label free quantitative nanoLC-MS/MS allowing the identification and quantification of 970 urinary proteins. We next focused on proteins exclusively regulated in severe obstructive nephropathy and identified Arginase 1 as a potential candidate molecule involved in the development of obstructive nephropathy, located at the crossroad of pro-and antifibrotic pathways. The reduced urinary abundance of Arginase 1 in obstructive nephropathy was verified in independent clinical samples using both Western blot and MRM analysis. These data were confirmed in situ in kidneys obtained from a mouse obstructive nephropathy model. In addition, we also observed increased expression of Arginase 2 and increased total arginase activity in obstructed mouse kidneys. mRNA expression analysis of the related arginase pathways indicated that the pro-fibrotic arginase-related pathway is activated during obstructive nephropathy. Taken

show abstract

“…Arginase exists in two isoforms, namely arginase-1 and arginase-2, both of which are responsible for the hydrolysis of arginine to ornithine and urea in the urea cycle. Of the two isoforms, arginase-1 demonstrates high levels of expression within the liver, whereas arginase-2 levels are highest in the kidneys and pancreas and very low in the liver [26]. …”

Section: Discussionmentioning

confidence: 99%

Arginase-1: A Highly Specific Marker Separating Pancreatic Adenocarcinoma from Hepatocellular Carcinoma

Fatima

Cohen²,

Siddiqui³

2013

Acta Cytologica

View full text Add to dashboard Cite

Background: Arginase-1 and HepPar-1 are effective immunohistochemical (IHC) markers for hepatocellular carcinoma (HCC). In this study, we explored the possible efficacy of these stains in diagnosing pancreatic adenocarcinoma (PAD). Study Design: Arginase-1 and HepPar-1 IHC was performed on formalin-fixed, paraffin-embedded fine needle aspiration (FNA) cell blocks (CB) of PAD (n = 46), tissue microarray (TMA) of PAD (n = 33), FNA CB of HCC (n = 44) and TMA of HCC (n = 85). Negative controls without carcinoma were also applied (pancreas CB, n = 7; pancreas TMA, n = 3). Results: PAD CB demonstrated arginase-1 positivity in 0 of 46 cases and HepPar-1 positivity in 7 of 46 cases (15%). PAD TMA demonstrated arginase-1 positivity in 0 of 33 cases and HepPar-1 positivity in 4 of 33 cases (12%). HCC CB demonstrated arginase-1 positivity in 37 of 44 cases (84%) and HepPar-1 positivity in 32 of 44 cases (72%). HCC TMA demonstrated arginase-1 positivity in 75 of 85 cases (88%) and HepPar-1 positivity in 80 of 85 cases (94%). Conclusion: Both arginase-1 and HepPar-1 are effective IHC markers of hepatocellular differentiation. Arginase-1 demonstrates superior sensitivity and specificity compared with HepPar-1 in the diagnosis of HCC. However, both arginase-1 and HepPar-1 have a low sensitivity and a very high specificity for PAD.

show abstract

Immunohistochemical study of arginase 1 and 2 in various tissues of rats

Cited by 64 publications

References 29 publications

Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma

Immunohistochemical pitfalls and the importance of glypican 3 and arginase in the diagnosis of scirrhous hepatocellular carcinoma

Label-free Quantitative Urinary Proteomics Identifies the Arginase Pathway as a New Player in Congenital Obstructive Nephropathy

Arginase-1: A Highly Specific Marker Separating Pancreatic Adenocarcinoma from Hepatocellular Carcinoma

Contact Info

Product

Resources

About